The hybrid capture-based NGS technology allows for the sensitive detection of clinically relevant point mutations, insertions, deletions, copy number alterations, translocations, microsatellite instability (MSI) and tumor mutational burden (TMB) in a single sample – for reliable cancer profiling results.


Our innovative assays for various questions in molecular pathology and clinical research are combined with bioinformatic evaluation and user-friendly data evaluation. Full data control on all raw and analysis files remains with the customer.



The analysis is based exclusively on DNA and enables optimized and tissue-saving processes in the laboratory. In establishing the technology, we offer our customers tailored support for efficient molecular tumor diagnostics.



Molecular cancer diagnostics in your laboratory


Media, scientific publications and conference abstracts

Who we are

The management team of New Oncology


Hybrid capture-based next generation sequencing

To top